Notable among these studies the GeparSixto study exploring the addition of carboplatin to neoadjuvant therapy for patients with early-stage TNBC as well as HER2-positive disease [26] demonstrated an improvement in pCR rate from 37.9% to 58.7% (P < 0.05) with the addition of carboplatin in the TNBC group but not in the HER2+ breast cancer group (33.1% with carboplatin and 36.3% without carboplatin, n.s.)(ASCO 2013, abstract 1004). This evidence concerns the gene ERBB2 and breast carcinoma.